MLKL

Across TCGA pan-cancer cohorts, MLKL Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MLKL data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MLKL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MLKL expression acts as an unfavorable survival marker.

KIRP, STAD, and BLCA are the cancer types where MLKL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.141	0.904	<.001	36	view →
STAD	OS	Median	All	0.184	0.730	.002	18	view →
BLCA	OS	Median	IV	0.089	0.599	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SCLC	OS	Median	All	0.055	0.653	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MLKL–KIRP (OS)

Open the KIRP breakdown →